富信科技(688662.SH):監事梁競新累計減持6.8萬股 減持時間已經過半
格隆匯8月13日丨富信科技(688662.SH)公佈,公司於2023年4月18日在上海證券交易所網站披露的《廣東富信科技股份有限公司關於部分監事減持股份計劃公吿》(公吿編號:2023-011),公司監事會主席梁競新先生計劃減持公司股份數量不超過73,250股,即不超過公司總股本的0.0830%。
2023年8月11日,公司收到上述股東出具的《關於股份減持進展的吿知函》,截至2023年8月11日,梁競新先生已通過集中競價交易方式累計減持68,000股,佔公司總股本的0.0771%。本次減持計劃時間已經過半,減持計劃尚未實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.